35 results on '"Roodman, David"'
Search Results
2. Fingolimod in Combination with Bortezomib Demonstrates Synergistic Tumor Inhibition and Bone Anabolic Effects in Myeloma Bone Disease
3. MIP-1α (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma
4. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1
5. Evaluating the Efficacy and Toxicity of Two Lenalidomide Dose Regimens for the Treatment of Older Relapsed Multiple Myeloma Patients with Co-Morbidities: A Multi-Site Study at the Veteran's Administration Hospitals
6. Bone-Targeted Pharmacological Inhibition of Notch Signaling As a Novel Approach to Inhibit Myeloma Growth and Bone Destruction
7. Aplidin (Plitidepsin) Regulates Viability and Function of Myeloma Cells and Bone Cells in Combination with Other Anti-MM Drugs
8. Once a Week Bortezomib with Dexamethasone Is Effective with Limited Toxicity in Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities,
9. Blocking the ZZ Domain of Sequestosome 1/p62 Suppress the Enhancement of Myeloma Cell Growth and Osteoclast Formation by Marrow Stromal Cells
10. Annexin II Interactions with the Annexin II Receptor Enhance Multiple Myeloma Cell Adhesion and Growth in the Bone Marrow Microenvironment,
11. The ZZ Domain of Sequestosome-1/p62 Plays An Important Role In Stromal Cell Support of Myeloma Cell Growth and Osteoclast Formation
12. Annexin II Interactions with the Annexin II Receptor Enhance Multiple Myeloma Cell Adhesion and Growth In the Bone Marrow Microenvironment
13. Interim Results of An Ongoing Clinical Study Suggests Efficacy and Improved Toxicity Profile with Once a Week Bortezomib with Dexamethasone In Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities
14. Combination of Bendamustine, Lenalidomide, and Dexamethasone In Patients with Refractory or Relapsed Multiple Myeloma Is Safe and Highly Effective: Results of a Phase I Clinical Trial
15. A Phase I Study of Bendamustine Combined with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma.
16. Characterization of Hepcidin-Inducing Cytokines in Multiple Myeloma.
17. p62 as a Therapeutic Target for Myeloma Cell Growth and Osteoclast Formation.
18. Increased Signaling through p62 in the Marrow Microenvironment Increases Myeloma Cell Growth and Osteoclast Formation
19. Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms.
20. Suppression of Mesenchymal Stromal Cell (MSC) Differentiation in Multiple Myeloma (MM) Is Restricted to the Osteoblast Lineage
21. Cooperation Between IL-7 and TNF-Alpha Results in Suppression of Runx2/Cbfa1 Expression and Inhibition of Osteoblast Differentiation in Myeloma.
22. Th-17 Lymphocytes, Not Regulatory T Cells, Mediate Immune Regulation of Bone Marrow Infiltrating Lymphocytes and Induce Osteoclast Activation in Multiple Myeloma.
23. Developing In Vivo Model for Studying Mechanisms of Osteoblast Suppression in Multiple Myeloma.
24. p62 Signaling Is Increased in Multiple Myeloma Microenvironment.
25. A Novel, Mercaptoketone-Based HDAC Inhibitor, KD5170 Exerts Marked Inhibition of Osteoclast Formation and Anti-Myeloma Activity In Vitro.
26. Targeting p62 in Marrow Stromal Cells Is Effective at Inhibiting Myeloma Cell Growth.
27. Herpes-Simplex Thymidine Kinase Gene as a Selective Marker in Evaluating the Bone Marrow Microenvironment in Multiple Myeloma (MM).
28. SDX-308, a Structural Analog of Etodolac, Inhibits NF-κB Activity Resulting in Significant Inhibition of Osteoclast Formation/Activity and Multiple Myeloma Cell Growth.
29. Combination of the Proteasome Inhibitor Bortezomib and a Histone Deacetylase Inhibitor PXD101 Results in Synergistic Inhibition of Osteoclastogenesis and Significantly Stronger Inhibition of Multiple Myeloma Growth In Vitro and In Vivo.
30. Thalidomide Derivative CC-4047 Inhibits Osteoclast Formation by down Regulation of PU.1.
31. Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms.
32. The CCR1 Antagonist BX470 Inhibits the Growth of Multiple Myeloma (MM) Cells That Produce MIP-1α.
33. Combination of Proteasome Inhibitor PS 341 (Velcade®) with Histone Acetylase Inhibitor (HDAC) PXD 101 Shows Superior Anti-Myeloma Activity and Inhibits Osteoclastogenesis.
34. Developing In VivoModel for Studying Mechanisms of Osteoblast Suppression in Multiple Myeloma.
35. Combination of the Proteasome Inhibitor Bortezomib and a Histone Deacetylase Inhibitor PXD101 Results in Synergistic Inhibition of Osteoclastogenesis and Significantly Stronger Inhibition of Multiple Myeloma Growth In Vitroand In Vivo.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.